Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of Calderasib (MK-1084)
NCT06942741Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calderasib in solid tumor (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration at 2 days, Area Under the Concentration-Time Curve From Time 0 to Infinity at 2 days and 8 more. Started May 2025; status: completed.
02
Drugs
calderasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06942741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942741.